FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006457199> ?p ?o ?g. }

• W2006457199 endingPage "183" @default.
• W2006457199 startingPage "177" @default.
• W2006457199 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jan 2002TAMSULOSIN FOR TREATING LOWER URINARY TRACT SYMPTOMS COMPATIBLE WITH BENIGN PROSTATIC OBSTRUCTION: A SYSTEMATIC REVIEW OF EFFICACY AND ADVERSE EFFECTS TIMOTHY J. WILT, RODERICK MacDONALD, and DAVID NELSON TIMOTHY J. WILTTIMOTHY J. WILT More articles by this author , RODERICK MacDONALDRODERICK MacDONALD More articles by this author , and DAVID NELSONDAVID NELSON More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65407-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We systematically reviewed the effectiveness and adverse effects of tamsulosin for lower urinary tract symptoms compatible with benign prostatic obstruction. Materials and Methods: Studies were included in analysis when they involved a randomized trial of at least 1 month in duration, men with lower urinary tract symptoms and a comparison of tamsulosin with placebo or an active control. Study, patient and outcome data were extracted onto standard forms using a prospective protocol. Results: Of the series 13 involving 3,418 men with a mean age of 64 years met our inclusion criteria. Study duration was 4 to 26 weeks. Baseline symptom scores and flow rates showed moderate lower urinary tract symptoms. Tamsulosin improved symptoms and peak urine flow compared with placebo. The weighted mean difference in the mean change from baseline for the Boyarsky symptom score for 0.4 and 0.8 mg. tamsulosin versus placebo was −1.1 (95% confidence interval [CI] −1.49 to −0.72 or 12% improvement) and −1.6 points (95% CI −2.3 to −1.0 or 16% improvement), respectively. The weighted mean difference in the mean change from baseline in peak urine flow was 1.1 (95% CI 0.59 to 1.51) and 1.1 ml. per second (95% CI 0.65 to 1.48) for 0.4 and 0.8 mg., respectively. The 0.2 to 0.4 mg. tamsulosin dose was as effective as other α-antagonists for improving symptoms and the flow rate, although the doses of all α-antagonists evaluated may not have been optimal. Treatment withdrawals and adverse effects increased markedly as the tamsulosin dose increased. Conclusions: Tamsulosin improves lower urinary tract symptoms and flow. Its effectiveness was similar to that of other α-antagonists, increasing slightly at higher doses. Adverse effects were generally mild but the incidence, including treatment withdrawals, increased substantially at higher doses. References 1 : High prevalence of benign prostatic hypertrophy in the community. Lancet1991; 338: 469. Google Scholar 2 : The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol1993; 150: 85. Link, Google Scholar 3 : Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol1989; 141: 248. Link, Google Scholar 4 : A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol1997; 158: 488. Link, Google Scholar 5 : Drug treatment for benign prostatic hyperplasia. Health authorities must audit use of finasteride. BMJ1997; 315: 370. Google Scholar 6 : Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol1997; 80: 521. Google Scholar 7 : α1-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal α1-adrenoceptors. Naunyn-Schmiede Arch Pharmacol1993; 348: 385. Google Scholar 8 : α1-Adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate, rate tissues and at cloned subtypes. Proceedings of Congress Société Internationale d’Urologie1994; : 254. abstract, Sydney, Australia, September 18–22, 1994. Google Scholar 9 : Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol1995; 288: 201. Google Scholar 10 : Identifying relevant studies for systematic reviews. BMJ1994; 312: 944. Google Scholar 11 : Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995; 273: 408. Google Scholar 12 : Meta-analysis in clinical trials. Control Clin Trials1986; 7: 177. Google Scholar 13 : Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br J Urol1995; 76: 325. Google Scholar 14 : A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol1997; 80: 587. Google Scholar 15 : Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol1996; 29: 155. Google Scholar 16 : Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J Urol1990; 144: 908. Abstract, Google Scholar 17 : Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology1998; 51: 892. Google Scholar 18 : A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. Members of United States 93–01 Study Group. J Urol1998; 160: 1701. Link, Google Scholar 19 : Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol1997; 80: 606. Google Scholar 20 : Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. Chinese Tamsulosin Study Group. J Med1998; 29: 289. Google Scholar 21 : A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int2000; 85: 676. Google Scholar 22 : Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol2000; 7: 199. Google Scholar 23 : Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol1997; 80: 597. Google Scholar 24 : Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Br J Urol1997; 80: 78. Google Scholar 25 : Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. Scand J Urol Nephrol1996; 30: 379. Google Scholar 26 : A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists inpatients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol1999; 36: 1. Google Scholar 27 : Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet1999; 354: 1896. Google Scholar 28 : Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA1996; 276: 637. Google Scholar 29 Available at http://www.drugstore.com/pharmacy/drugindex Accessed March 10, 2001 Google Scholar From the Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Cochrane Review Group in Prostate Diseases and Urologic Cancers, Veterans Affairs Medical Center, Minneapolis, Minnesota© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byNieminen T, Tammela T, Kööbi T and Kähönen M (2018) The Effects of Tamsulosin and Sildenafil in Separate and Combined Regimens on Detailed Hemodynamics in Patients With Benign Prostatic EnlargementJournal of Urology, VOL. 176, NO. 6, (2551-2556), Online publication date: 1-Dec-2006. Volume 167Issue 1January 2002Page: 177-183 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsurination disordersadrenergic alpha-antagonistsprostatic hyperplasiaprostateMetricsAuthor Information TIMOTHY J. WILT More articles by this author RODERICK MacDONALD More articles by this author DAVID NELSON More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2006457199 created "2016-06-24" @default.
• W2006457199 creator A5007116853 @default.
• W2006457199 creator A5043350291 @default.
• W2006457199 creator A5050308696 @default.
• W2006457199 date "2002-01-01" @default.
• W2006457199 modified "2023-10-16" @default.
• W2006457199 title "TAMSULOSIN FOR TREATING LOWER URINARY TRACT SYMPTOMS COMPATIBLE WITH BENIGN PROSTATIC OBSTRUCTION: A SYSTEMATIC REVIEW OF EFFICACY AND ADVERSE EFFECTS" @default.
• W2006457199 cites W100997517 @default.
• W2006457199 cites W1557253144 @default.
• W2006457199 cites W1983391475 @default.
• W2006457199 cites W1991011333 @default.
• W2006457199 cites W2000442546 @default.
• W2006457199 cites W2006100624 @default.
• W2006457199 cites W2011932878 @default.
• W2006457199 cites W2017365683 @default.
• W2006457199 cites W2031763102 @default.
• W2006457199 cites W2057942596 @default.
• W2006457199 cites W2058207372 @default.
• W2006457199 cites W2082612334 @default.
• W2006457199 cites W2085293854 @default.
• W2006457199 cites W2101665942 @default.
• W2006457199 cites W2107328434 @default.
• W2006457199 cites W2135421268 @default.
• W2006457199 cites W2144504916 @default.
• W2006457199 cites W2144563350 @default.
• W2006457199 cites W2148496159 @default.
• W2006457199 cites W2341507669 @default.
• W2006457199 cites W2405109010 @default.
• W2006457199 cites W4319720823 @default.
• W2006457199 cites W751950711 @default.
• W2006457199 doi "https://doi.org/10.1016/s0022-5347(05)65407-9" @default.
• W2006457199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11743300" @default.
• W2006457199 hasPublicationYear "2002" @default.
• W2006457199 type Work @default.
• W2006457199 sameAs 2006457199 @default.
• W2006457199 citedByCount "53" @default.
• W2006457199 countsByYear W20064571992012 @default.
• W2006457199 countsByYear W20064571992013 @default.
• W2006457199 countsByYear W20064571992014 @default.
• W2006457199 countsByYear W20064571992015 @default.
• W2006457199 countsByYear W20064571992016 @default.
• W2006457199 countsByYear W20064571992017 @default.
• W2006457199 countsByYear W20064571992018 @default.
• W2006457199 countsByYear W20064571992019 @default.
• W2006457199 countsByYear W20064571992020 @default.
• W2006457199 countsByYear W20064571992022 @default.
• W2006457199 countsByYear W20064571992023 @default.
• W2006457199 crossrefType "journal-article" @default.
• W2006457199 hasAuthorship W2006457199A5007116853 @default.
• W2006457199 hasAuthorship W2006457199A5043350291 @default.
• W2006457199 hasAuthorship W2006457199A5050308696 @default.
• W2006457199 hasConcept C121608353 @default.
• W2006457199 hasConcept C126322002 @default.
• W2006457199 hasConcept C126894567 @default.
• W2006457199 hasConcept C197934379 @default.
• W2006457199 hasConcept C2776235491 @default.
• W2006457199 hasConcept C2777562237 @default.
• W2006457199 hasConcept C2779478474 @default.
• W2006457199 hasConcept C2780542891 @default.
• W2006457199 hasConcept C71924100 @default.
• W2006457199 hasConcept C77411442 @default.
• W2006457199 hasConceptScore W2006457199C121608353 @default.
• W2006457199 hasConceptScore W2006457199C126322002 @default.
• W2006457199 hasConceptScore W2006457199C126894567 @default.
• W2006457199 hasConceptScore W2006457199C197934379 @default.
• W2006457199 hasConceptScore W2006457199C2776235491 @default.
• W2006457199 hasConceptScore W2006457199C2777562237 @default.
• W2006457199 hasConceptScore W2006457199C2779478474 @default.
• W2006457199 hasConceptScore W2006457199C2780542891 @default.
• W2006457199 hasConceptScore W2006457199C71924100 @default.
• W2006457199 hasConceptScore W2006457199C77411442 @default.
• W2006457199 hasIssue "1" @default.
• W2006457199 hasLocation W20064571991 @default.
• W2006457199 hasLocation W20064571992 @default.
• W2006457199 hasOpenAccess W2006457199 @default.
• W2006457199 hasPrimaryLocation W20064571991 @default.
• W2006457199 hasRelatedWork W1991511992 @default.
• W2006457199 hasRelatedWork W2049932762 @default.
• W2006457199 hasRelatedWork W2100669542 @default.
• W2006457199 hasRelatedWork W2102736746 @default.
• W2006457199 hasRelatedWork W2141781475 @default.
• W2006457199 hasRelatedWork W2143580412 @default.
• W2006457199 hasRelatedWork W2607090108 @default.
• W2006457199 hasRelatedWork W3013025230 @default.
• W2006457199 hasRelatedWork W3021917722 @default.
• W2006457199 hasRelatedWork W4205328221 @default.
• W2006457199 hasVolume "167" @default.
• W2006457199 isParatext "false" @default.
• W2006457199 isRetracted "false" @default.
• W2006457199 magId "2006457199" @default.
• W2006457199 workType "article" @default.